DE69333115D1 - Rekombinante viren, die an ihrer äusseren oberfläche ein nichtvirales polypeptid präsentieren - Google Patents

Rekombinante viren, die an ihrer äusseren oberfläche ein nichtvirales polypeptid präsentieren

Info

Publication number
DE69333115D1
DE69333115D1 DE69333115T DE69333115T DE69333115D1 DE 69333115 D1 DE69333115 D1 DE 69333115D1 DE 69333115 T DE69333115 T DE 69333115T DE 69333115 T DE69333115 T DE 69333115T DE 69333115 D1 DE69333115 D1 DE 69333115D1
Authority
DE
Germany
Prior art keywords
gene
particles
hapten
retroviral
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69333115T
Other languages
English (en)
Inventor
Stephen James Russell
Robert Edward Hawkins
Gregory Paul Winter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biofocus Discovery Ltd
Original Assignee
Biofocus Discovery Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929220010A external-priority patent/GB9220010D0/en
Priority claimed from GB939304962A external-priority patent/GB9304962D0/en
Application filed by Biofocus Discovery Ltd filed Critical Biofocus Discovery Ltd
Application granted granted Critical
Publication of DE69333115D1 publication Critical patent/DE69333115D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13045—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • C12N2810/859—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from immunoglobulins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE69333115T 1992-09-22 1993-09-22 Rekombinante viren, die an ihrer äusseren oberfläche ein nichtvirales polypeptid präsentieren Expired - Lifetime DE69333115D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB929220010A GB9220010D0 (en) 1992-09-22 1992-09-22 Recombinant virus
GB939304962A GB9304962D0 (en) 1993-03-11 1993-03-11 Recombinant virus
PCT/GB1993/001992 WO1994006920A1 (en) 1992-09-22 1993-09-22 Recombinant viruses displaying a nonviral polypeptide on their external surface

Publications (1)

Publication Number Publication Date
DE69333115D1 true DE69333115D1 (de) 2003-08-28

Family

ID=26301664

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69333115T Expired - Lifetime DE69333115D1 (de) 1992-09-22 1993-09-22 Rekombinante viren, die an ihrer äusseren oberfläche ein nichtvirales polypeptid präsentieren

Country Status (8)

Country Link
US (2) US5723287A (de)
EP (1) EP0670905B1 (de)
JP (1) JPH08504091A (de)
AT (1) ATE245703T1 (de)
AU (1) AU689755B2 (de)
CA (1) CA2145063A1 (de)
DE (1) DE69333115D1 (de)
WO (1) WO1994006920A1 (de)

Families Citing this family (124)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69333115D1 (de) * 1992-09-22 2003-08-28 Biofocus Discovery Ltd Rekombinante viren, die an ihrer äusseren oberfläche ein nichtvirales polypeptid präsentieren
EP0746625B1 (de) * 1992-11-09 2004-03-31 THE UNITED STATES GOVERNMENT as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Erzielbare vektorenpartikel
US6534051B1 (en) 1992-11-20 2003-03-18 University Of Medicine And Dentistry Of New Jersey Cell type specific gene transfer using retroviral vectors containing antibody-envelope fusion proteins and wild-type envelope fusion proteins
JPH08504098A (ja) * 1992-11-20 1996-05-07 ユニバーシティー オブ メディスン アンド デンティストリー オブ ニュー ジャージー 抗体−エンベロープ融合蛋白を含有するレトロウィルスベクターを用いた細胞種特異的な遺伝子転移
US5869331A (en) * 1992-11-20 1999-02-09 University Of Medicine & Dentistry Of New Jersey Cell type specific gene transfer using retroviral vectors containing antibody-envelope fusion proteins and wild-type envelope fusion proteins
EP0744958B1 (de) 1994-01-31 2003-06-25 Trustees Of Boston University Bibliotheken aus polyklonalen antikörpern
US20060078561A1 (en) * 1994-01-31 2006-04-13 The Trustees Of Boston University Polyclonal antibody libraries
US6150137A (en) 1994-05-27 2000-11-21 Ariad Pharmaceuticals, Inc. Immunosuppressant target proteins
US5846782A (en) 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US6465253B1 (en) 1994-09-08 2002-10-15 Genvec, Inc. Vectors and methods for gene transfer to cells
FR2724320B1 (fr) * 1994-09-13 1996-12-20 Transgene Sa Nouvel implant pour le traitement des maladies acquises
US5518042A (en) * 1994-09-16 1996-05-21 Huyck Licensco, Inc. Papermaker's forming fabric with additional cross machine direction locator and fiber supporting yarns
US5770442A (en) 1995-02-21 1998-06-23 Cornell Research Foundation, Inc. Chimeric adenoviral fiber protein and methods of using same
US6127525A (en) * 1995-02-21 2000-10-03 Cornell Research Foundation, Inc. Chimeric adenoviral coat protein and methods of using same
GB9506782D0 (en) * 1995-04-01 1995-05-24 British Biotech Pharm Retroviral vectors
GB9514368D0 (en) * 1995-07-13 1995-09-13 Medical Res Council Improvements in or relating to binding assays
GB9516138D0 (en) * 1995-08-05 1995-10-04 Medical Res Council Improvements in or relating to methods of screening substances
WO1997012048A1 (en) * 1995-09-27 1997-04-03 Medical Research Council Recombinant viruses incorporating a protease cleavable protein
GB9519776D0 (en) 1995-09-28 1995-11-29 Casimir Colin Materials and methods relating to the transfer of nucleic acid into stem cells
DE69722176T2 (de) 1996-01-23 2004-03-18 The Board Of Trustees Of The Leland Stanford Junior University, Palo Alto Verfahren zur suche nach transdominanten effektorpeptiden und rna-molekülen
US6365344B1 (en) 1996-01-23 2002-04-02 The Board Of Trustees Of The Leland Stanford Junior University Methods for screening for transdominant effector peptides and RNA molecules
AU2670397A (en) * 1996-04-08 1997-10-29 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Reagent and method for targeting retrovirus
CA2283461A1 (en) * 1997-03-14 1998-09-17 Uab Research Foundation Adenoviral vectors with modified tropism
NZ500006A (en) 1997-04-10 2001-09-28 Univ Southern California Modified retroviral vector particle proteins which bind extracellular matrix components including collagen
GB9709421D0 (en) 1997-05-10 1997-07-02 Zeneca Ltd Chemical compounds
US6004798A (en) * 1997-05-14 1999-12-21 University Of Southern California Retroviral envelopes having modified hypervariable polyproline regions
WO1998055611A1 (en) * 1997-06-06 1998-12-10 Regents Of The University Of Michigan Neuregulin response element and uses therefor
NZ516848A (en) 1997-06-20 2004-03-26 Ciphergen Biosystems Inc Retentate chromatography apparatus with applications in biology and medicine
AU2002301047B2 (en) * 1997-06-20 2005-11-10 Ciphergen Biosystems, Inc. Retentate Chromatography And Protein Chip Arrays With Applications In Biology And Medicine
US7078483B2 (en) 1998-04-29 2006-07-18 University Of Southern California Retroviral vectors including modified envelope escort proteins
AU4089899A (en) 1998-05-20 1999-12-06 University Of Tennessee Research Corporation, The Stable envelope proteins for retroviral, viral and liposome vectors and use in gene and drug therapy
CA2334170A1 (en) 1998-07-27 2000-02-10 Genentech, Inc. Improved transformation efficiency in phage display through modification of a coat protein
WO2000008131A2 (en) * 1998-08-04 2000-02-17 Purdue Research Foundation Pseudotyped retroviruses and stable cell lines for their production
US7033595B1 (en) 1998-08-04 2006-04-25 Purdue Research Foundation Pseudotyped retroviruses and stable cell lines for their production
CA2345392A1 (en) * 1998-09-24 2000-03-30 Duke University Method of measuring protein-protein interactions in living cells
EP1123114B1 (de) * 1998-10-21 2005-12-28 THE UNITED STATES GOVERNMENT as represented by THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Virusähnliche partikel zur induktion von autoantikörpern
JP2000279178A (ja) * 1999-02-24 2000-10-10 Japan Found Cancer Res ウイルスベクター
US6890726B1 (en) 1999-04-06 2005-05-10 Oklahoma Medical Research Foundation Method for selecting recombinase variants with altered specificity
US7803765B2 (en) * 1999-05-05 2010-09-28 Phylogica Limited Methods of constructing biodiverse gene fragment libraries and biological modulators isolated therefrom
US7270969B2 (en) * 1999-05-05 2007-09-18 Phylogica Limited Methods of constructing and screening diverse expression libraries
CA2372464C (en) 1999-05-05 2012-07-31 Phylogica Limited Isolating biological modulators from biodiverse gene fragment libraries
US7396905B1 (en) 1999-05-21 2008-07-08 Mckeon Frank Calcipressins: endogenous inhibitors of calcineurin, uses and reagents related thereto
AU5464000A (en) * 1999-06-01 2000-12-18 University Of Washington Recombinant adenoviral vectors for cell specific infection and genome integration and expressing chimeric fiber proteins
US7094398B1 (en) 1999-06-01 2006-08-22 University Of Washington Recombinant adenoviral vectors expressing chimeric fiber proteins for cell specific infection and genome integration
US6955808B2 (en) * 1999-09-24 2005-10-18 Uab Research Foundation Capsid-modified recombinant adenovirus and methods of use
US6555368B1 (en) 1999-09-24 2003-04-29 Uab Research Foundation Capsid-modified recombinant adenovirus and methods of use
EP1223947A4 (de) * 1999-10-15 2004-12-08 Canji Inc Zielgerichtete vektoren
IL149809A0 (en) * 1999-12-15 2002-11-10 Genentech Inc Shotgun scanning, a combinatorial method for mapping functional protein epitopes
WO2001062970A1 (en) * 2000-02-25 2001-08-30 Cambridge Drug Discovery, Ltd. Methods and compositions for identifying a protease
WO2001062972A1 (en) * 2000-02-25 2001-08-30 Biofocus Discovery Limited Methods for identifying candidate polynucleotide molecules encoding a protease
DE60115405T2 (de) * 2000-03-31 2006-08-03 Cambridge Antibody Technology Ltd. Verbesserungen in bezug auf ribosom-komplexe als selektionspartikel
US6762031B2 (en) 2000-06-16 2004-07-13 University Of Medicine And Dentistry Of New Jersey Targeting viral vectors to specific cells
DE60126130T2 (de) * 2000-11-17 2007-10-18 The University Of Rochester In-vitro verfahren zur herstellung und identifizierung von immunglobulin moleküle in eukaryotischen zellen
US20050196755A1 (en) * 2000-11-17 2005-09-08 Maurice Zauderer In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells
US20030104402A1 (en) * 2001-01-23 2003-06-05 University Of Rochester Methods of producing or identifying intrabodies in eukaryotic cells
US7541512B2 (en) 2001-03-30 2009-06-02 Synageva Biopharma Corp. Avians containing a lysozyme promoter transgene
AU2002255995A1 (en) 2001-03-30 2002-10-15 Avigenics, Inc. Avian lysozyme promoter
US7176300B2 (en) 2001-03-30 2007-02-13 Avigenics, Inc. Avian lysozyme promoter
US6867189B2 (en) 2001-07-26 2005-03-15 Genset S.A. Use of adipsin/complement factor D in the treatment of metabolic related disorders
US7550650B2 (en) 2001-09-18 2009-06-23 Synageva Biopharma Corp. Production of a transgenic avian by cytoplasmic injection
US7294507B2 (en) 2001-11-30 2007-11-13 Avigenics, Inc. Ovomucoid promoters and methods of use
US7335761B2 (en) 2001-11-30 2008-02-26 Avigenics, Inc. Avian gene expression controlling regions
US6875588B2 (en) 2001-11-30 2005-04-05 Avigenics, Inc. Ovomucoid promoter and methods of use
SI1461428T1 (sl) 2001-12-03 2012-07-31 Alexion Pharma Inc Postopek za proizvodnjo hibridnih protiteles
US7255874B1 (en) 2001-12-21 2007-08-14 Closure Medical Corporation Biocompatible polymers and adhesives: compositions, methods of making and uses related thereto
US20050069549A1 (en) 2002-01-14 2005-03-31 William Herman Targeted ligands
US7132237B2 (en) * 2002-03-13 2006-11-07 Mayo Foundation For Medical Education And Research Avian leukosis viruses and polypeptide display
US7135562B2 (en) 2002-03-14 2006-11-14 University Of Cincinnati Avian iFABP gene expression controlling region
US20040038304A1 (en) * 2002-03-28 2004-02-26 Gala Design, Inc. Antibody libraries
US7981656B2 (en) * 2002-06-04 2011-07-19 Purdue Research Foundation Pseudotyped retrovirus with modified ebola glycoprotein
CA2421269A1 (en) 2002-08-09 2004-02-09 President And Fellows Of Harvard College Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
US7329486B2 (en) * 2003-03-31 2008-02-12 The Board Of Regents Of The University Of Texas System High-throughput assay for virus entry and drug screening
US20060025337A1 (en) 2003-07-01 2006-02-02 President And Fellows Of Harvard College Sirtuin related therapeutics and diagnostics for neurodegenerative diseases
US8507277B2 (en) 2003-10-24 2013-08-13 Gencia Corporation Nonviral vectors for delivering polynucleotides
CA2543257C (en) 2003-10-24 2013-12-31 Gencia Corporation Methods and compositions for delivering polynucleotides
US8133733B2 (en) 2003-10-24 2012-03-13 Gencia Corporation Nonviral vectors for delivering polynucleotides to target tissues
US8062891B2 (en) 2003-10-24 2011-11-22 Gencia Corporation Nonviral vectors for delivering polynucleotides to plants
US20090123468A1 (en) 2003-10-24 2009-05-14 Gencia Corporation Transducible polypeptides for modifying metabolism
WO2005118647A2 (en) * 2004-05-18 2005-12-15 Genentech, Inc. M13 virus major coat protein variants for c-terminal and bi-terminal display of a heterologous protein
DK1754052T3 (en) * 2004-06-03 2015-09-28 Phylogica Ltd Modulators with biochemical properties
US7875275B2 (en) 2004-06-16 2011-01-25 The General Hospital Corporation Use of Bridge-1 and activators and inhibitors thereof in the treatment of insulin deficiency and diabetes
AU2005262329A1 (en) * 2004-07-01 2006-01-19 Virxsys Corporation Vector packaging cell line
JP2008506703A (ja) 2004-07-14 2008-03-06 ユニバーシティ オブ ユタ リサーチ ファウンデーション ネトリン関連化合物および用途
WO2006022944A2 (en) * 2004-07-21 2006-03-02 Dana-Farber Cancer Institute, Inc. Lentiviral vectors and uses thereof
LT5414B (lt) * 2005-04-13 2007-04-25 Biotechnologijos Institutas Monokloninių antikūnų gavimo būdas, hibridomos, gautos šiuo būdu ir rekombinantinės chimerinės į virusus panašios dalelės su įterptais kitų baltymų fragmentais kaip imunogenai hibridomų gavimui šiuo būdu
EP2963118B1 (de) * 2005-06-01 2017-08-09 California Institute of Technology Verfahren zur gezielten genabgabe über virale vektoren
JP5102630B2 (ja) * 2005-11-24 2012-12-19 ジェノミディア株式会社 改変パラミクソウイルスおよびその作製方法
CA2950465A1 (en) 2006-02-20 2007-08-30 Phylogica Limited Method of constructing and screening libraries of peptide structures
PT2048955E (pt) 2006-07-21 2013-09-20 California Inst Of Techn Administração de gene alvo para vacinação de células dendríticas
EP2074138A4 (de) * 2006-09-19 2009-12-30 Phylogica Ltd Neuroprotektive peptidinhibitoren der ap-1-signalvermittlung und anwendungen davon
US20100104572A1 (en) * 2006-11-02 2010-04-29 Sylvie Luria Methods for screening for therapeutic molecules and use of the molecules therefrom
WO2008092041A2 (en) 2007-01-24 2008-07-31 Carnegie Mellon University Optical biosensors
DE602007013110D1 (de) * 2007-04-04 2011-04-21 Chimera Biotec Gmbh Verfahren zum nachweis eines analyten in einer biologischen matrix
US8822409B2 (en) * 2007-06-20 2014-09-02 Phylogica Limited Compositions and uses thereof for the treatment of acute respiratory distress syndrome (ARDS) and clinical disorders associated with therewith
US7928189B2 (en) 2008-05-05 2011-04-19 Ottawa Health Research Institute PCSK9 polypeptide fragment
ATE523603T1 (de) * 2008-11-21 2011-09-15 Chimera Biotec Gmbh Konjugatkomplexe zum analytnachweis
US8492133B2 (en) 2009-01-20 2013-07-23 Ramot At Tel Aviv University, Ltd. MIR-21 promoter driven targeted cancer therapy
US9719069B2 (en) 2009-01-27 2017-08-01 University Of Utah Research Foundation Methods and compositions relating to viral latency
ES2900277T3 (es) 2009-03-20 2022-03-16 Mesoblast Inc Producción de células pluripotentes reprogramadas
JP5802195B2 (ja) 2009-04-27 2015-10-28 オタワ ホスピタル リサーチ インスティチュート 幹細胞を調節するための組成物および方法ならびにその使用
BRPI1011195B1 (pt) * 2009-05-20 2020-10-13 Novimmune S.A métodos para produzir uma coleção de ácidos nucleicos
AU2010276194B2 (en) 2009-07-24 2012-02-02 Immune Design Corp Lentiviral vectors pseudotyped with a Sindbis virus envelope glycoprotein
US8926976B2 (en) 2009-09-25 2015-01-06 Xoma Technology Ltd. Modulators
CA2772945A1 (en) 2009-09-25 2011-03-31 Xoma Technology Ltd. Screening methods
CA2823194A1 (en) 2010-12-27 2012-07-05 Brown University Therapeutic and diagnostic methods involving biglycan and utrophin
US10208304B2 (en) 2011-04-14 2019-02-19 Regents Of The University Of Minnesota Adenovirus library and methods
CA2833404A1 (en) 2011-04-21 2012-10-26 Garvan Institute Of Medical Research Modified variable domain molecules and methods for producing and using them b
KR102148982B1 (ko) 2011-06-03 2020-08-27 조마 테크놀로지 리미티드 Tgf-베타에 특이적인 항체
EP2844746A4 (de) 2012-03-26 2016-07-20 Univ California Pseudotypisierte lentiviren mit nipah-virus-hüllen und verfahren zu deren verwendung
US9713635B2 (en) 2012-03-30 2017-07-25 Immune Design Corp. Materials and methods for producing improved lentiviral vector particles
PT2831095T (pt) 2012-03-30 2019-01-30 Immune Design Corp Partículas de vectores lentivirais com melhor eficácia de transdução de células que expressam dc-sign
US8323662B1 (en) 2012-03-30 2012-12-04 Immune Design Corp. Methods useful for generating highly mannosylated pseudotyped lentiviral vector particles comprising a Vpx protein
WO2014201426A2 (en) 2013-06-14 2014-12-18 University Of Utah Research Foundation Triazol-1-ol analogs anti-retroviral latency drugs
EP3265491A1 (de) 2015-03-03 2018-01-10 Xoma (Us) Llc Behandlung von postprandialer hyperinsulinämie und hyperglykämie nach bariatrischer chirurgie
EP3735982A1 (de) 2015-03-10 2020-11-11 The University of Massachusetts Abzielung auf gdf6 und bmp-signalisierung für antimelanomtherapie
CN108136001B (zh) 2015-04-03 2022-07-29 佐马技术有限公司 使用TGF-β抑制剂和PD-1抑制剂治疗癌症
HK1255271A1 (zh) 2015-08-06 2019-08-09 Xoma (Us) Llc 针对胰岛素受体的抗体片段和其治疗低血糖的用途
EP3458481A4 (de) 2016-05-18 2020-07-29 Mayo Foundation for Medical Education and Research Targeting von pd-l1 auf tumorzellen
JP7148493B2 (ja) 2016-08-01 2022-10-05 ゾーマ （ユーエス） リミテッド ライアビリティ カンパニー 副甲状腺ホルモン受容体１（ｐｔｈ１ｒ）抗体およびその使用
AU2017335771A1 (en) 2016-09-28 2019-02-28 Musc Foundation For Research Development Antibodies that bind interleukin-2 and uses thereof
KR102761577B1 (ko) 2017-05-08 2025-02-03 플래그쉽 파이어니어링 이노베이션스 브이, 인크. 막 융합을 촉진시키기 위한 조성물 및 그의 용도
CN112955174A (zh) 2018-07-09 2021-06-11 旗舰先锋创新V股份有限公司 融合剂脂质体组合物和其用途
CN113631718A (zh) 2018-11-14 2021-11-09 旗舰先锋创新V股份有限公司 用于特定隔室货物递送的组合物和方法
ES2967696T3 (es) 2019-04-08 2024-05-03 Giuseppe Scalabrino Factor de crecimiento epidérmico (EGF) y variantes del mismo para tratar o prevenir trastornos desmielinizantes inflamatorios

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990012087A1 (en) * 1989-04-05 1990-10-18 Novacell Corporation Infectious targetted replication-defective virion
AU665176B2 (en) * 1990-09-21 1995-12-21 Novartis Vaccines And Diagnostics, Inc. Packaging cells
DE69131908T3 (de) * 1991-02-19 2008-04-03 Oxford Biomedica (Uk) Ltd. Viruspartikel mit veraendertem wirtspektrum
WO1993000103A1 (en) * 1991-06-21 1993-01-07 The Wistar Institute Of Anatomy And Biology Chimeric envelope proteins for viral targeting
AU2512792A (en) * 1991-08-30 1993-04-05 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Defective interfering hiv particles with chimeric cd4-env
AU3434393A (en) * 1992-01-17 1993-08-03 Regents Of The University Of Michigan, The Targeted virus
CA2133411A1 (en) * 1992-04-03 1993-10-14 Alexander T. YOUNG Gene therapy using targeted viral vectors
DE69333115D1 (de) * 1992-09-22 2003-08-28 Biofocus Discovery Ltd Rekombinante viren, die an ihrer äusseren oberfläche ein nichtvirales polypeptid präsentieren

Also Published As

Publication number Publication date
EP0670905A1 (de) 1995-09-13
JPH08504091A (ja) 1996-05-07
AU689755B2 (en) 1998-04-09
CA2145063A1 (en) 1994-03-31
WO1994006920A1 (en) 1994-03-31
ATE245703T1 (de) 2003-08-15
EP0670905B1 (de) 2003-07-23
US5723287A (en) 1998-03-03
US6297004B1 (en) 2001-10-02
AU4827893A (en) 1994-04-12

Similar Documents

Publication Publication Date Title
DE69333115D1 (de) Rekombinante viren, die an ihrer äusseren oberfläche ein nichtvirales polypeptid präsentieren
Kasahara et al. Tissue-specific targeting of retroviral vectors through ligand-receptor interactions
Jones et al. Human T-cell leukemia virus type 1 (HTLV-1) and HTLV-2 use different receptor complexes to enter T cells
Lavillette et al. Activation of a cell entry pathway common to type C mammalian retroviruses by soluble envelope fragments
Morizono et al. Role of phosphatidylserine receptors in enveloped virus infection
Siomi et al. Sequence requirements for nucleolar localization of human T cell leukemia virus type I pX protein, which regulates viral RNA processing
Goila-Gaur et al. Defects in human immunodeficiency virus budding and endosomal sorting induced by TSG101 overexpression
Cheynet et al. Synthesis, assembly, and processing of the Env ERVWE1/syncytin human endogenous retroviral envelope
Ou et al. Specific targeting of human interleukin (IL)-13 receptor α2-positive cells with lentiviral vectors displaying IL-13
AU4427389A (en) Peptides and antibodies that inhibit integrin-ligand binding
CA2285937A1 (en) Modified proteins which bind extracellular matrix components
AU4545889A (en) Synthetic dna derived recombinant hiv antigens
Lavillette et al. Activation of membrane fusion by murine leukemia viruses is controlled in cis or in trans by interactions between the receptor-binding domain and a conserved disulfide loop of the carboxy terminus of the surface glycoprotein
AU4602596A (en) Retroviral delivery of full length factor viii
AU1189195A (en) Recombinant protein production in bovine adenovirus expression vector system
BRPI9811940A (pt) vetor de expressão para um polipeptídeo de ligação da interleucina-18 (il-18-bp), célula hospedeira procariótica transformada com o referido vetor, processo para produção de il-18-bp, proteína de fusão compreendendo o referido polipeptídeo, bem como il-18bp modificada.
MY102594A (en) Expression of plasmodium falciparum polypeptides from cloney cdna
JP2002522090A (ja) 抗体エンベロープ融合タンパク質および野生型エンベロープタンパク質を含有するレトロウイルスベクターを用いる細胞型特異的遺伝子移入
Dreja et al. The effects of N-terminal insertion into VSV-G of an scFv peptide
Battini et al. Definition of a 14-amino-acid peptide essential for the interaction between the murine leukemia virus amphotropic envelope glycoprotein and its receptor
Voelkel et al. Pseudotype-independent nonspecific uptake of gammaretroviral and lentiviral particles in human cells
Snitkovsky et al. A TVA–single-chain antibody fusion protein mediates specific targeting of a subgroup A avian leukosis virus vector to cells expressing a tumor-specific form of epidermal growth factor receptor
WO1999060110A2 (en) Stable envelope proteins for retroviral, viral and liposome vectors and use in gene and drug therapy
Bachrach et al. Efficient cell infection by Moloney murine leukemia virus-derived particles requires minimal amounts of envelope glycoprotein
Guibinga et al. Ligand-modified vesicular stomatitis virus glycoprotein displays a temperature-sensitive intracellular trafficking and virus assembly phenotype

Legal Events

Date Code Title Description
8332 No legal effect for de